![](https://cdn.sanity.io/images/0vv8moc6/hcplive/1cd0db0f9691d63a994fb1c8808f562595b1ec69-300x300.jpg?fit=crop&auto=format)
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X
Four-year data from the RHONE-X extension study demonstrated the continued durability, efficacy, and safety of faricimab (Vabysmo) for the treatment of patients with diabetic macular edema (DME). These late-breaking data, presented at the American Society …